|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate in a prospective study, the performance of Quantiferon-TB-Gold in tube (QFT) in vitro assay compared to the conventional tuberculin skin test (TST) in detecting LTBI among a cohort of non-BCG-vaccinated patients with moderate-to-severe psoriasis during long-term treatment (12 months) with TNF-alpha antagonists.
|
21923840 |
2012 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-24 was strongly expressed in human psoriatic epidermis, and pharmacological inhibition of NF-κB increased IL-24 expression in TNF-stimulated human primary keratinocytes, suggesting that this mechanism is relevant for human psoriasis.
|
24211183 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis suggests that TNF-α 308 G/A polymorphism is associated with decreased risk of psoriasis, while TNF-α 238 G/A is associated with increased risk of psoriasis.
|
24324571 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pituitary tumor transforming gene 1 induces tumor necrosis factor-α production from keratinocytes: implication for involvement in the pathophysiology of psoriasis.
|
23677169 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
|
24048425 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Notably, administration of soluble IL-15Rα was able to repress secretion of IL-1β, IL-6, and TNF by keratinocytes, dampen expansion of IL-17(+) αβ and γδ T cells in vivo, and prevent psoriasis in two mouse models, including human xenograft AGR mice.
|
24019554 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data show that an early critical event for the clinical remission of psoriasis in response to TNF inhibitors is the inhibition of the CCR7/CCL19 axis and support its role in psoriasis pathogenesis.
|
23731727 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that there were a three-way interaction among IL21, CCR4 and TNF(χ(2) = 5.02(1), P = 0.025) and three pair-wise gene-gene interactions between IL12RB1 and CCR4(χ(2) = 11.66(4), P = 0.0201), IL22 and CCR4 (χ(2) = 11.97(4), P = 0.0176), IL12RB1 and IL6 (χ(2) = 7.31(1), P = 0.0069) in psoriasis.
|
22909235 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.
|
23337970 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to analyze the effects of anti-TNF-α treatment on TNF-α(+) cells in the skin and blood of patients with psoriasis.
|
23890755 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paradoxically, there have been numerous reports of new-onset psoriasis following tumor necrosis factor-α antagonist therapy in adult patients with inflammatory bowel disease, but pediatric data are sparse.
|
23274341 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the TNF-α -238 and -308 promoter polymorphisms may play different roles in conferring susceptibility to psoriasis.
|
24252077 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis patients treated with etanercept rapidly decrease cutaneous IL-17C levels, suggesting IL-17C/TNF-α-mediated inflammatory signaling is critical for psoriasis pathogenesis.
|
23359500 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
|
23662788 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By contrast, healthy individuals homozygous for the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interacting domain and previously associated with psoriasis, had impaired, but not abolished, responses to IL-17 cytokines.
|
24120361 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As for the TNFα (-238 G/A) polymorphism, a significant increase of the GG genotype was observed in patients, especially men with second- and third-degree relatives with psoriasis (Pg = 0.008).
|
23834030 |
2013 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Psoriasis (Ps) is an autoimmune disease characterized by keratinocyte hyperproliferation and chronic inflammation, with increased expression of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF).
|
24587411 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α plays a crucial role in psoriasis; therefore, TNF inhibition has become a gold standard for the treatment of psoriasis.
|
25384035 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The responses of patients with psoriasis to TNFα-antagonists show interindividual differences.
|
24476008 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our primary objective was to assess the HPV DNA prevalence in psoriasis patients treated with TNF inhibitors and the secondary objective was to assess the same parameter before and during treatment.
|
24206262 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results support an association between susceptibility to psoriasis and TNF polymorphisms in the Spanish population.
|
24135300 |
2014 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNFα overexpression has been associated with several chronic inflammatory diseases, including psoriasis, lichen planus, rheumatoid arthritis, and inflammatory bowel disease.
|
24802997 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicated that TNF-α-308 and IL-10-1082 polymorphisms imparted significant risk towards the development of psoriasis.
|
24594293 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The management of RA, SpA, psoriasis and inflammatory bowel disease has significantly improved over the last decade with the addition of tumour necrosis factor inhibitors (anti-TNFs) to the therapeutic armamentarium.
|
23946436 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of this study are an important step in the characterization of the pharmacogenetic profile associated with anti-TNF response in psoriasis.
|
25403996 |
2015 |